Sequence: NH2-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-COOH
| Experiment Id | EXP002398 |
|---|---|
| Paper | Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multi |
| Peptide | MMP2 substrate |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | liposomal formulation; lipids molar ratio PC:DSPE-PEG(2000)-TAT:Chol:DOPE:DOTAP = 6:1:5:2:3 (plus post-inserted cetuximab micelles) |
| Rna Concentration | 50 nM siBCRP (encapsulated) |
| Mixing Ratio | encapsulation into liposome (not free peptide/siRNA complex) |
| Formulation Format | enzyme-sensitive, TAT and cetuximab functionalized immunoliposome |
| Formulation Components | DOTAP, DOPE, PC, cholesterol, DSPE-PEG(2000)-TAT, MAL-PEG(3000)-MMP2-DOPE, cetuximab |
| Size Nm | 157.90 |
| Zeta Mv | 28.90 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MCF7-MX (mitoxantrone-resistant breast cancer cells); MCF7 used for expression comparisons |
| Animal Model | |
| Administration Route | cell culture treatment with siRNA-loaded liposomes; uptake by flow cytometry (DiI) and functional assays at 24–48 h |
| Output Type | gene silencing, chemosensitization |
| Output Value | BCRP mRNA ~0.24-fold; BCRP protein ~0.2-fold at 48 h; mitoxantrone IC50 reduced ~4-fold with TAT+Cetuximab+ |
| Output Units | |
| Output Notes | Flow cytometry shows increased uptake for TAT+Cetuximab+ vs controls; qPCR + western blot confirm BCRP knockdown; chemosensitization to mitoxantrone. |
| Toxicity Notes | Nanoparticle IC10/IC50 reported; targeted formulations more cytotoxic; used IC10 for silencing assays. |
| Curation Notes |